| A protective bivalent vaccine against Rift Valley fever and bluetongue E Calvo-Pinilla, A Marín-López, S Moreno, G Lorenzo, S Utrilla-Trigo, ... npj Vaccines 5 (1), 70, 2020 | 26* | 2020 |
| Heterologous combination of ChAdOx1 and MVA vectors expressing protein NS1 as vaccination strategy to induce durable and cross-protective CD8+ T cell immunity to bluetongue virus S Utrilla-Trigo, L Jiménez-Cabello, R Alonso-Ravelo, E Calvo-Pinilla, ... Vaccines 8 (3), 346, 2020 | 23 | 2020 |
| Epizootic hemorrhagic disease virus: Current knowledge and emerging perspectives L Jiménez-Cabello, S Utrilla-Trigo, G Lorenzo, J Ortego, E Calvo-Pinilla Microorganisms 11 (5), 1339, 2023 | 18 | 2023 |
| Viral vector vaccines against bluetongue virus L Jiménez-Cabello, S Utrilla-Trigo, E Calvo-Pinilla, S Moreno, A Nogales, ... Microorganisms 9 (1), 42, 2020 | 18 | 2020 |
| Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design E Calvo-Pinilla, A Marín-López, S Utrilla-Trigo, L Jiménez-Cabello, ... Current opinion in virology 44, 49-56, 2020 | 14 | 2020 |
| Inhibition of orbivirus replication by aurintricarboxylic acid C Alonso, S Utrilla-Trigo, E Calvo-Pinilla, L Jiménez-Cabello, J Ortego, ... International Journal of Molecular Sciences 21 (19), 7294, 2020 | 11 | 2020 |
| The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical … S Utrilla-Trigo, L Jiménez-Cabello, E Calvo-Pinilla, A Marín-López, ... Journal of Virology 96 (3), e01614-21, 2022 | 9 | 2022 |
| Nanoparticle-and microparticle-based vaccines against orbiviruses of veterinary importance L Jiménez-Cabello, S Utrilla-Trigo, N Barreiro-Piñeiro, T Pose-Boirazian, ... Vaccines 10 (7), 1124, 2022 | 5 | 2022 |
| Vaccinia virus strain MVA expressing a prefusion-stabilized SARS-CoV-2 Spike glycoprotein induces robust protection and prevents brain infection in mouse and hamster models MM Lorenzo, A Marín-López, K Chiem, L Jimenez-Cabello, I Ullah, ... Vaccines 11 (5), 1006, 2023 | 4 | 2023 |
| Cytokine mRNA Expression Profile in Target Organs of IFNAR (-/-) Mice Infected with African Horse Sickness Virus E Calvo-Pinilla, L Jiménez-Cabello, S Utrilla-Trigo, M Illescas-Amo, ... International Journal of Molecular Sciences 25 (4), 2065, 2024 | 1 | 2024 |
| Engineering recombinant replication-competent bluetongue viruses expressing reporter genes for in vitro and non-invasive in vivo studies S Utrilla-Trigo, L Jiménez-Cabello, A Marín-López, M Illescas-Amo, ... Microbiology Spectrum 12 (3), e02493-23, 2024 | | 2024 |
| IFNAR (-/-) Mice Constitute a Suitable Animal Model for Epizootic Hemorrhagic Disease Virus Study and Vaccine Evaluation L Jiménez-Cabello, S Utrilla-Trigo, J Benavides-Silván, J Anguita, ... International Journal of Biological Sciences 20 (8), 3076, 2024 | | 2024 |
| Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus A Marín-López, S Utrilla-Trigo, L Jiménez-Cabello, J Ortego Vaccine Technologies for Veterinary Viral Diseases: Methods and Protocols …, 2022 | | 2022 |
| Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus L Jiménez-Cabello, S Utrilla-Trigo, EVA CALVO, G Lorenzo, ... Frontiers in Immunology 15, 1440407, 0 | | |
